Inhibitors to coagulation factors

The proceeding papers investigate the integration of modern concepts of immunology and hematology toward the design of potential new therapies for the prevention or elimination of antibodies to F.VIII and F.IX. The current research anticipates gene therapy for hemophilias and the implications of inhibitors in such a course of treatment. Papers include discussions on: the molecular and antigenic structure of factors VIII and IX and von Willebrand factor, the human immune response molecular basis, genetic variation and the immune response, inhibitor treatment, coagulation tolerance, and panel discussions.